Last reviewed · How we verify
CT-388
At a glance
| Generic name | CT-388 |
|---|---|
| Also known as | RO7795068, RG6640 |
| Sponsor | Carmot Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes (PHASE3)
- A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight Without Type 2 Diabetes (PHASE3)
- A Study of CT-388 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity (PHASE2)
- A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus (PHASE2)
- A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CT-388 CI brief — competitive landscape report
- CT-388 updates RSS · CI watch RSS
- Carmot Therapeutics, Inc. portfolio CI